The company has opened its Qualified Institutions Placement (QIP) issue on November 13. The floor price has been fixed at Rs ...

Buy APLS near 28.9 target 36.47 stop loss @ 28.82 Details The technical summary data tells us to buy APLS near 28.9 with an ...

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on APLS stock, giving a Hold rating on November 4. Graig ...

Wells Fargo analyst Derek Archila has maintained their neutral stance on APLS stock, giving a Hold rating yesterday. Derek Archila has given his Hold rating due to a combination of factors impacting ...

Apellis unveiled those results before market hours on Tuesday, disclosing that its revenue for the quarter was just under $197 million. That was ...

On Friday, Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $27.98 which represents a slight increase of $0.72 or 2.64% from the prior close of $27.26. The stock opened ...